We have data that indicate if we use the same selection criteria used in the pivotal studies of high-risk nmCRPC and perform a PET/PSMA in these patients, up to 55% of them would be identified as having metastatic disease [42]. This evidence concerns the gene FOLH1 and metastatic neoplasm.